[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368028-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368028-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-inspector-study-enhanced-feasibility-for-clinical-translation-of-a-multi-cancer-early-detection-method-based-on-enzyme-assisted-high-signal-to-noise-ratio-sequencing-of-methylated-circulating-tumor-dna","The INSPECTOR study - enhanced feasibility for clinical translation of a multi-cancer early detection method based on enzyme-assisted high signal-to-noise ratio sequencing of methylated circulating tumor DNA","","Blood-based cell-free DNA (cfDNA) methylation testing is positioned as a promising route to multi-cancer early detection (MCED), yet conventional bisulfite methods may limit sensitivity for early-stage malignancies and certain cancer types. The INSPECTOR study introduces an MCED and cancer signal origin (CSO) system tailored for early-stage or hard-to-detect cancers, using enzyme-assisted high signal-to-noise ratio sequencing of methylated circulating tumor DNA.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-inspector-study-enhanced-feasibility-for-clinical-translation-of-a-multi-cancer-early-detection-method-based-on-enzyme-assisted-high-signal-to-noise-ratio-sequencing-of-methylated-circulating-tumor-dna/368028/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-inspector-study-enhanced-feasibility-for-clinical-translation-of-a-multi-cancer-early-detection-method-based-on-enzyme-assisted-high-signal-to-noise-ratio-sequencing-of-methylated-circulating-tumor-dna/368028.png","ImageObject",300,407,{"name":42,"@type":43},"mieayamfan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the INSPECTOR study address in multi-cancer early detection?","Question",{"text":63,"@type":64},"Traditional bisulfite-based methylation testing can face sensitivity limitations for early-stage malignancies and some cancer types. INSPECTOR aims to improve feasibility and performance for these challenging scenarios.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the INSPECTOR approach detect cancer signals?",{"text":68,"@type":64},"It uses an enzyme-assisted whole-methylome sequencing strategy (human TET enzyme-assisted) to build methylation markers and a targeted panel, enabling MCED and CSO modeling from methylated circulating tumor DNA.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical validation performance is reported?",{"text":72,"@type":64},"Clinical validation across multi-center case-control cohorts reports high specificity around 99% and sensitivity in the low-to-mid 80% range depending on cohort, with stage-specific sensitivities described for early cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368028,1790459480,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":30,"preview_urls":147},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","DOI: 10.1002/cac2.70071  \nORIGINAL ARTICLE  \nThe INSPECTOR study: enhanced feasibility for clinical translation of a multi-cancer early detection method based on enzyme-assisted high signal-to-noise ratio sequencing of methylated circulating tumor DNA  \nHui-Yan Luo1,2   Wei Wei2, 3,4  Pansong Li5  Qi-Hua Zhang2, 6  Zhipeng Zhou7 Liang Cui7  Yong-Bin Lin8  Hong Yang8  Xianyu Zhong5  Qingfeng Liu5  HanYang8  Kong-Jia Luo8  Hai-Bo Qiu9   Shu-Qiang Yuan9   \nYuan-Fang Li9   Zhi-Wei Zhou9   Xiao-Jun Lin10  Bo-Kang Cui10   \nRong-Xin Zhang11  Wen-Hua Fan11  He Huang12  Chun-Yan Lan12   \nJun-Dong Li12  Zhi-Qiang Wang1  Bin-Kui Li3  Rong-Ping Guo3   Jun Tang13 Xin Huang13   Mian Xi14   Yuying Liu15  Chuanbo Xie15  Shi Chen16  Zhi-Hu Li17  Yu-Hua Liu17  Xiao-Ting Zhang18  Qiang Zeng19   Xin Yi7  Rui-Hua Xu1,2   \nCorrespondence:  \nRui-Hua Xu, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.  \n[Email:](Email: xurh@sysucc.org.cn)[ xurh@sysucc.org.cn](Email: xurh@sysucc.org.cn)  \nHui-Yan Luo, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.  \nEmail: [luohy@sysucc.org.cn](luohy@sysucc.org.cn)  \nAbstract  \nBackground: Blood-based cell-free DNA (cfDNA) methylation testing has emerged as a promising approach for multi-cancer early detection (MCED), holding the potential to improve cancer survival rates. However, traditional bisulfite-based methods often encounter sensitivity limitations in detecting early-stage malignancies or certain cancer types. In the INSPECTOR study, we developed a MCED and cancer signal origin (CSO) system specifically designed for early-stage or hard-to-detect cancers, including those of the lung, breast, colorectum, liver, esophagus, stomach, pancreas, and ovary.  \nList of Abbreviations: INSPECTOR, Innovative and Noninvasive Screening with Plasma-based Early-Cancer Test for Optimal Results; cfDNA, Cell-free DNA; MCED, Multi-cancer early detection; CSO, Cancer signal origin; hTET, Human TET; GM-seq, Human TET enzyme-assisted  \nwhole-methylome-sequencing; NGS, Next-generation-sequencing; LDCT, Low-dose computed tomography; CCGA3, Circulating Cell-free Genome Atlas 3; BS-seq, Bisulfite genomic sequencing; 5mC, 5-methylcytosine; AJCC, American Joint Committee on Cancer; 5caC, 5-carboxyl cytosine; DHU, Dihydrouracil; QC, Quality control; WGBS, Whole genome bisulfite sequencing; UMI, Unique molecular identifier; ROC, Receiver operating characteristic curve; LoD, Limit of detection; GO, Gene Ontology; t-SNE, t-Stochastic neighbor embedding; AUC, Area under the curve; CSO1, Top-1 predicted origin; CSO2, Top-2 predicted origin; SCLC, Small cell lung cancer; LUSC, Lung squamous cell carcinoma; LUAD, Lung adenocarcinoma; TNBC, Triple-negative breast cancer; NSCLC, Non-small cell lung cancer; MFR, Methylated fragment ratio.  \nHui-Yan Luo, Wei Wei, and Pansong Li contributed equally as co-first authors.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2025 The Author(s) . Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.  \nLUO et al.  \nXin Yi, Department of Precision Medicine, GenePlus-Beijing Institute, Beijing, P. R. China. [Email:](Email: yix@geneplus.org.cn)[ yix@geneplus.org.cn](Email: yix@geneplus.org.cn)  \nFunding information  \nNoncommunicable Chronic  \nDiseases-National Science and Technology Major Project, Grant/Award Numbers: 2023ZD0501600, 2024D0533304; National Natural Science Foundation of China, Grant/Award Numbers: 92374114, 82273402, 82321003, 82173128, 81930065; Natural Science Foundation of Guangdong Province, Grant/Award Numbers: 2024A1515012888, 2014A030312015, 2019A1515011109; Science and Technology","cbCaim3zeUzba5oq","https://ap.wps.com/l/cbCaim3zeUzba5oq","pdf",3559490,21,"English","# Abstract\n## Background\n## Methods\n## Results\n## Funding and publication notes","[{\"question\":\"What problem does the INSPECTOR study address in multi-cancer early detection?\",\"answer\":\"Traditional bisulfite-based methylation testing can face sensitivity limitations for early-stage malignancies and some cancer types. INSPECTOR aims to improve feasibility and performance for these challenging scenarios.\"},{\"question\":\"How does the INSPECTOR approach detect cancer signals?\",\"answer\":\"It uses an enzyme-assisted whole-methylome sequencing strategy (human TET enzyme-assisted) to build methylation markers and a targeted panel, enabling MCED and CSO modeling from methylated circulating tumor DNA.\"},{\"question\":\"What clinical validation performance is reported?\",\"answer\":\"Clinical validation across multi-center case-control cohorts reports high specificity around 99% and sensitivity in the low-to-mid 80% range depending on cohort, with stage-specific sensitivities described for early cancers.\"}]","The INSPECTOR study - enhanced feasibility for clinical translation of a multi-cancer early detection method based on enzyme-assisted high signal-to-noise ratio sequencing of methylated circulating tumor DNA | PDF",1790174456,53,[148,152,156],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/9078bba14070365d4ebb67f1362e8453.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/aacea681b7c272de27dca185525522d4.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/a5d7395749d163e134224715e7e2952f.webp",981,1289]